Anna Mae Diehl
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Year:
2026
We report the design and preclinical evaluation of a unimolecular dual agonist, GLP1-ELP-FGF21 (GEF), which integrates GLP-1 and FGF21 signaling by linking GLP-1 and FGF21 through a thermally responsive elastin-like polypeptide (ELP) linker. GEF was engineered for optimal receptor engagement and extended pharmacokinetics through reversible phase separation into a depot upon subcutaneous injection. GEF retained potent in vitro activity at both GLP-1R and FGFR1/β-Klotho pathways and demonstrated robust metabolic and hepatic benefits in a diet-induced murine model of advanced MASH. Treatment with GEF significantly reduced body weight, liver mass, serum glucose levels, and total cholesterol, while also attenuating hepatic inflammation and fibrosis. Molecular and histological analyses revealed suppressed expression of pro-fibrotic and inflammatory genes, reduced steatosis, and enhanced hepatocyte proliferation. Collectively, these findings establish GEF as a promising single-agent, multi-pathway therapeutic for treating advanced MASH.
Year:
2025
Clinical translation of AAV-mediated gene therapy requires preclinical development across different experimental models, often confounded by variable transduction efficiency. Here, we describe a human liver chimeric transgene-free Il2rg −/− /Rag2 −/− /Fah −/− /Aavr −/− (TIRFA) mouse model overcoming this translational roadblock, by combining liver humanization with AAV receptor (AAVR) ablation, rendering murine cells impermissive to AAV transduction. Using human liver chimeric TIRFA mice, we demonstrate increased transduction of clinically used AAV serotypes in primary human hepatocytes compared to humanized mice with wild-type AAVR. Further, we demonstrate AAV transduction in human teratoma-derived primary cells and liver cancer tissue, displaying the versatility of the humanized TIRFA mouse. From a mechanistic perspective, our results support the notion that AAVR functions as both an entry receptor and an intracellular receptor essential for transduction. The TIRFA mouse should allow prediction of AAV gene transfer efficiency and the study of AAV vector biology in a preclinical human setting.
Year:
2024
Background and Aims: Senescent hepatocytes accumulate in parallel with fibrosis progression during NASH. The mechanisms that enable progressive expansion of nonreplicating cell populations and the significance of that process in determining NASH outcomes are unclear. Senescing cells upregulate thrombomodulin–protease-activated receptor-1 (THBD-PAR1) signaling to remain viable. Vorapaxar blocks the activity of that pathway. We used vorapaxar to determine if and how THBD-PAR1 signaling promotes fibrosis progression in NASH. Approach and Results: We evaluated the THBD-PAR1 pathway in liver biopsies from patients with NAFLD. Chow-fed mice were treated with viral vectors to overexpress p16 in hepatocytes and induce replicative senescence. Effects on the THBD-PAR1 axis and regenerative capacity were assessed; the transcriptome of p16-overexpressing hepatocytes was characterized, and we examined how conditioned medium from senescent but viable (dubbed “undead”) hepatocytes reprograms HSCs. Mouse models of NASH caused by genetic obesity or Western diet/CCl 4 were treated with vorapaxar to determine effects on hepatocyte senescence and liver damage. Inducing senescence upregulates the THBD-PAR1 signaling axis in hepatocytes and induces their expression of fibrogenic factors, including hedgehog ligands. Hepatocyte THBD-PAR1 signaling increases in NAFLD and supports sustained hepatocyte senescence that limits effective liver regeneration and promotes maladaptive repair. Inhibiting PAR1 signaling with vorapaxar interrupts this process, reduces the burden of ‘undead’ senescent cells, and safely improves NASH and fibrosis despite ongoing lipotoxic stress. Conclusion: The THBD-PAR1 signaling axis is a novel therapeutic target for NASH because blocking this pathway prevents accumulation of senescing but viable hepatocytes that generate factors that promote maladaptive liver repair.
Year:
2023
Collaborators (6)
Aravind Asokan
Professor/Director
Duke University
Karl-Dimiter Bissig
Associate Professor
Duke University
Charles Gersbach
John W. Strohbehn Distinguished Professor
Duke University
Nhu Thao Galvan
Associate Professor of Surgery
Baylor College of Medicine
Kuo Du
Assistant Professor
University of Kansas Medical Center
Rajesh Kumar Dutta
Research Associate, Senior
Duke University
Make your next move.
Prepare your application
Review drafts before you send them.